Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Colon Carcinoma Metastatic in the Liver · Metastatic Melanoma · VCNX

Vaccinex

VACCINEX, INC.

Vaccinex patent portfolio — 41 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
1895 Mt Hope Ave, Rochester, New York 14620, US HQ
28 Employees
Public company Type
VCNX · NYSE Ticker
Company details
Status
Public
HQ
1895 Mt Hope Ave, Rochester, New York 14620, US
Employees
28
Programs
11
Drugs
8
Patents
41
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Vaccinex patents

41 pharmaceutical patents indexed for Vaccinex. 0 expire within 24 months.

Vaccinex has 41 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

41 patents

Patent portfolio

  1. US 12201719

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12070500

    Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12006365

    Human anti-semaphorin 4D antibody

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12006364

    Anti-CD100 antibodies and methods for using the same

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11981730

    Anti-CXCL13 antibodies and methods of using the same

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11859000

    Anti-CCR8 antibodies and uses thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11660330

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11597765

    Use of semaphorin-4D binding molecules for the treatment of Rett syndrome

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11572408

    Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11534488

    Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11427634

    Human anti-semaphorin 4D antibody

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11274149

    Anti-CD100 antibodies and methods for using the same

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11078295

    Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10829550

    Polynucleotides encoding anti-CXCL13 antibodies

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10800853

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10526414

    Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10494440

    Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10385136

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10301393

    Methods of treating multiple sclerosis using anti-CD20 antibodies

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10111950

    Modified glycolipids and methods of making and using the same

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9963504

    Anti-CXCL13 antibodies and methods of using the same

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9890213

    Methods for the treatment of B cell-mediated inflammatory diseases

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9828435

    Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9790271

    Methods for increasing immunoglobulin A levels

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9676840

    Anti-CD100 neutralizing antibodies and methods of using the same

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9603922

    Modulation of NKT cell activity with antigen-loaded CD1d molecules

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9605055

    Anti-CD100 antibodies and methods of using the same

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9598495

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9512224

    Use of semaphorin-4D binding molecules for treatment of atherosclerosis

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9382327

    Anti-CD20 antibodies and methods of use

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9371352

    Modified glycolipids and methods of making and using the same

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9249227

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9243068

    Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8834883

    Anti-VEGF antibodies and uses thereof

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8816058

    Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8790652

    Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis

    Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8637026

    Anti-C35 antibody combination therapies and methods

    Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8496938

    Anti-CD100 neutralizing neutralizing antibodies and methods of using the same

    Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7919594

    Human anti-CD100 antibodies

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7919095

    Anti-IL-6 monoclonal antibodies

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7807168

    Selection of human TNFα specific antibodies

    Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vaccinex have?

41 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vaccinex patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.